These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4002346)

  • 1. Lipid bound sialic acid in cancer patients.
    Salvagno L; Ferrazzi E; Sileni VC; Maggi S; Tredese F; Bedendo C; Russo MP; Fiorentino MV; Ceriotti G
    Tumori; 1985 Apr; 71(2):127-33. PubMed ID: 4002346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative study of serum lipid-bound sialic acid and carcinoembryonic antigen in patients with lung cancer].
    Zhu X
    Zhonghua Jie He He Hu Xi Za Zhi; 1990 Feb; 13(1):25-7, 61. PubMed ID: 2165867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer patients.
    Dnistrian AM; Schwartz MK
    Clin Chem; 1981 Oct; 27(10):1737-9. PubMed ID: 7285326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-bound sialic acid as a tumor marker.
    Dnistrian AM; Schwartz MK
    Ann Clin Lab Sci; 1983; 13(2):137-42. PubMed ID: 6859805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of plasma lipid-bound sialic acid (LBSA) and carcinoembryonic antigen (CEA) in gynaecologic cancer patients.
    Tredese F; Maggino T; Salvagno L; Marchesoni D; Chizzolini M; Pattaro RF
    Eur J Gynaecol Oncol; 1985; 6(2):136-8. PubMed ID: 4029198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature.
    Schutter EM; Visser JJ; van Kamp GJ; Mensdorff-Pouilly S; van Dijk W; Hilgers J; Kenemans P
    Tumour Biol; 1992; 13(3):121-32. PubMed ID: 1626178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of lipid-bound sialic acid (LSA) as a tumor marker.
    López Sáez JJ; Senra-Varela A
    Int J Biol Markers; 1995; 10(3):174-9. PubMed ID: 8551061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum lipid-bound sialic acid as a marker in lung cancer patients].
    Iwahashi N
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Dec; 28(12):1599-607. PubMed ID: 2077205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
    Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
    Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy.
    Stringou E; Chondros K; Kouvaris J; Kakari S; Papavassiliou K
    Anticancer Res; 1992; 12(1):251-5. PubMed ID: 1567173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of determining lipid-bound sialic acid for the diagnosis and further prognosis of cancer.
    Polívková J; Vosmiková K; Horák L
    Neoplasma; 1992; 39(4):233-6. PubMed ID: 1436234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relation between lipid-bound sialic acid in blood serum and plasma andin human tumors].
    Polívková J; Vosmiková K; Pospísil J; Poucková P
    Bratisl Lek Listy; 1992 May; 93(5):222-4. PubMed ID: 1393642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma lipid-bound sialic acid alterations in neoplastic diseases.
    Dwivedi C; Dixit M; Hardy RE
    Experientia; 1990 Jan; 46(1):91-4. PubMed ID: 2298288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behavior of serum sialic acid levels at various stages of neoplastic disease].
    Adamo V; Altavilla G; Caristi N; Chillemi S; Giacobello T; Scalisi R; Palmara D
    Minerva Med; 1985 Nov; 76(43):2067-70. PubMed ID: 4069416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K; Bian M; Zhu D; Liu W; Siu S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing benefits of combining biochemical and immunological markers in patients with lung carcinoma.
    Patel PS; Raval GN; Rawal RR; Patel GH; Balar DB; Shah PM; Patel DD
    Cancer Lett; 1994 Jul; 82(2):129-33. PubMed ID: 8050082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor markers in the monitoring of ovarian cancer].
    Xu SX
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of neopterin determination as a tumour marker in ovarian cancer.
    Szarka G; Pulay T; Csömör S; Tran-Phoung-Mai ; Schumann B
    Acta Chir Hung; 1988; 29(4):359-64. PubMed ID: 3239335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of lipid bound sialic acid and acute phase proteins in patients with cancer and nonmalignant disease.
    Raynes JG
    Biomed Pharmacother; 1983; 37(3):136-8. PubMed ID: 6605767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum lipid-bound sialic acid as a tumoral marker in minimal residual tumors.
    Musset M; Mathé G; Reizenstein P
    Suppl J Med Oncol Tumor Pharmacother; 1988; 1():17-20. PubMed ID: 3249552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.